(Q40874936)

24 September 2017

1 reference

title

The sympathetic nervous system and the renin-angiotensin-aldosterone system in cardiovascular disease (English)

1 reference

24 September 2017

R J Cody

1

1 reference

24 September 2017

language of work or name

English

0 references

publication date

1 November 1997

1 reference

American Journal of Cardiology

24 September 2017

published in

1 reference

24 September 2017

volume

80

1 reference

24 September 2017

issue

9B

1 reference

24 September 2017

page(s)

9J-14J

1 reference

The contributions of sympathetic tone and the renin-angiotensin system to severe chronic congestive heart failure: response to specific inhibitors (prazosin and captopril).

24 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900832-1

Plasma norepinephrine in congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900832-1

CATECHOLAMINE EXCRETION AND CARDIAC STORES OF NOREPINEPHRINE IN CONGESTIVE HEART FAILURE

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900832-1

Early Left Ventricular Dysfunction Elicits Activation of Sympathetic Drive and Attenuation of Parasympathetic Tone in the Paced Canine Model of Congestive Heart Failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900832-1

Cardiac secretion of atrial natriuretic factor with exercise in chronic congestive heart failure patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900832-1

Plasma volume, osmolality, vasopressin, and renin activity during graded exercise in man.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900832-1

The search for the ideal positive inotropic agent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900832-1

Sympathoinhibitory responses to digitalis glycosides in heart failure patients. Direct evidence from sympathetic neural recordings.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900832-1

The clinical potential of renin inhibitors and angiotensin antagonists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900832-1

The integrated effects of angiotensin II.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900832-1

Prospects for cardioreparation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900832-1

Angiotensin II induces plasminogen activator inhibitor-1 and -2 expression in vascular endothelial and smooth muscle cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900832-1

Sympathetic responsiveness and plasma norepinephrine during therapy of chronic congestive heart failure with captopril

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900832-1

Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900832-1

Mechanisms governing the postural response and baroreceptor abnormalities in chronic congestive heart failure: effects of acute and long-term converting-enzyme inhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900832-1

A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900832-1

Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900832-1

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900832-1

Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: a double-blind, randomized, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900832-1

Effects of bucindolol on neurohormonal activation in congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900832-1

Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900832-1

Value of carvedilol in congestive heart failure secondary to coronary artery disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900832-1

Effects of vesnarinone on morbidity and mortality in patients with heart failure. Vesnarinone Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900832-1

Blood pressure control by the renin-angiotensin system in normotensive subjects. Assessment by angiotensin converting enzyme and renin inhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900832-1

Propranolol inhibition of renin secretion. A specific approach to diagnosis and treatment of renin-dependent hypertensive diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900832-1

10.1016/S0002-9149(97)00832-1

7 January 2021

Identifiers

DOI

1 reference

24 September 2017

1 reference